Research

New discoveries in lung cancer research, such as the research funded by LCFA, are resulting in new treatments for lung cancer patients

How LCFA uses your donation wisely to fight lung cancer:

You Make A Donation to LCFA
Your dollars are added to contributions from other donors




We maximize your donation by adding it to dollars from LCFA’s strategic funding partners.


This leveraged donation allows LCFA to award a generous grant to a top young lung cancer investigator for 2 years of focused and intense research.


The lung cancer investigator
can now start the critical two-year process of research and discovery

Now, armed with this new evidence, the lung cancer investigator presents their findings to organizations like the National Institutes of Health (NIH) for consideration for vital next-stage grants.

Each painstaking step brings us closer to understanding how lung cancer works, how to detect it earlier, how to fight it better, and – someday – how to cure it.



Latest In Research

07/14
2017

New CDC Report Shows Deaths from Cancer Higher in Rural America

The CDC's July 7, 2017 Morbidity and Mortality Weekly Report shows a slower reduction in cancer death rates in rural America compared with urban America. “While geography alone can’t predict your risk of cancer, it can impact preventio…

07/6
2017

Full FDA Approval Granted for Anti-Cancer Drug Targeting EGFR Protein Found in Lung Cancer and Mesothelioma

Good news for Mesothelioma patients: FDA approves Tagrisso for lung cancer patients with the EGFR T790M mutation. Learn More…

06/27
2017

FDA Approves Tafinlar, Mekinist Combo to Treat BRAF V600E Non-Small Cell Lung Cancer

The U.S. Food and Drug Administration (FDA) announced approval of Tafinlar (dabrafenib) and Mekinist (trametinib) to be delivered in combination for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V60…

06/20
2017

With Patients Reporting Symptoms Using Web Tool, Survival Improves

An online tool that allows metastatic cancer patients to report their symptoms and grade them on severity is helping improve their survival, according to a study reported at the recent meetings of the American Society of Clinical Oncology m…

06/7
2017

Combined immune checkpoint blockade shows promise for small cell lung cancer

Small Cell Lung Cancer news: The combination of nivolumab plus ipilimumab led to durable responses in previously treated patients with small cell lung cancer, according to results from the CheckMate 032 trial presented at the 2017 ASCO Annu…

06/7
2017

ASCO 2017: Alectinib halts lung cancer growth more than a year longer than crizotinib

Findings from a phase III clinical trial point to a more effective initial treatment for patients with ALK-positive non-small cell lung cancer (NSCLC). Learn more More Lung Cancer Research News:…

05/22
2017

Lab on a Chip Outlines New Liquid Biopsy Technology

Lab on a Chip publication outlines a new technology that may be an important tool for liquid biopsies. Read the UCLA Patient Newsletter Read the abstract…

05/18
2017

A newly released study shows that Durvalumab (Imfinzi) significantly improved progression-free survival when used as a sequential treatment in patients with locally-advanced, unresectable non–small cell lung cancer (NSCLC) who had not pro…

05/12
2017

FDA Approves Keytruda Combo for Lung Cancer

The Food and Drug Administration (FDA) has granted an accelerated approval to Keytruda (pembrolizumab) for use in combination with chemotherapy as a frontline treatment for patients with metastatic or advanced nonsquamous non–small cell l…

05/4
2017

Brigatinib

On April 28, 2017, the U.S. Food and Drug Administration granted accelerated approval to brigatinib for the treatment of patients with metastatic anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) who have progress…

05/1
2017

FDA Grants Lorlatinib Breakthrough Designation for NSCLC

[caption id="attachment_1562" align="aligncenter" width="850"] Senior woman with lung cancer during medical visit[/caption] FDA Grants Lorlatinib Breakthrough Designation for NSCLC: “This regulatory designation recognizes the potential for…

04/28
2017

DNA-based test can spot cancer recurrence a year before conventional scans

A revolutionary blood test has been shown to diagnose the recurrence of cancer up to a year in advance of conventional scans in a major lung cancer trial. Read more…

04/18
2017

Pre-surgical Immunotherapy Trial to Open at UCLA Main Campus

Pre-surgical Immunotherapy Trial UCLA Main Campus: Stage IB, II, IIIA non-small cell lung cancer Exciting announcement from Thoracic Oncology Translational Research at UCLA: Upcoming opening of a pre-surgical immunotherapy trial for…

04/18
2017

AACR Annual Meeting 2017: Panel Discusses the Affordable Care Act

Can we make the ACA better? The legislation was the focus of a panel held at the American Association for Cancer Research Annual Meeting 2017. Read more: http://blog.aacr.org/aacr-annual-meeting-2017-panel-discusses-affordable-care-a…

04/18
2017

AACR Annual Meeting 2017: Immunotherapy Provides Long-lasting Responses to Certain Cancer Types

  Are responses to immunotherapy for lung cancer durable? According to data presented at AACR's 2017 Annual Meeting, from a number of clinical trials, the answer appears to be “Yes.” For many patients whose cancers responded …

04/11
2017

Phase III Study Shows Genentech’s Alecensa® Was Superior to Crizotinib in a Specific Type of Lung Cancer

A recent study shows that Alecensa® as an initial (first-line) treatment significantly reduced the risk of disease worsening or death compared to crizotinib in people with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell …

04/5
2017

Drug Offers Some Hope for a Deadly Lung Cancer

The cancer drug Opdivo (nivolumab) may offer hope of a longer life for some patients with advanced lung cancer, a new small study finds. Currently, only about 5 percent of patients with advanced non-small-cell lung cancer survive five years …

03/27
2017

‘Bad luck’ mutations increase cancer risk more than behavior, study says

For the first time, researchers have estimated what percentage of cancer mutations are due to environmental and lifestyle factors, hereditary factors and random chance. Overall, 66% of the genetic mutations that develop into cancer are caused…

03/16
2017

Frontline Immunotherapy Trial for EGFR Mutation Positive Patients to Expand Enrollment

Announcing the investigator initiated trial Pembro IST is anticipated to expand enrollment to UCLA satellite sites. Pembrolizumab is an antibody that inhibits the PD-1/PD-L1 immune checkpoint and allows the immune system to des…

03/14
2017

Advice From Patients On A Study’s Design Makes For Better Science

Clinical Trials News:  NCI-MATCH trial upends the normal way of classifying cancers for treatment: Instead of categorizing malignancies by the organ where they first appear, this method of sorting focuses on particular mutations in the ge…

03/7
2017

Update: CRISPR

Scientists say they’ll someday be able to use CRISPR to fight cancer and maybe even bring animals back from the dead. Read the story: http://www.radiolab.org/story/update-crispr/…

02/14
2017

Trial for Patients Doing Well on Nivolumab Expands to UCLA

The Checkmate 384 study will is now available at UCLA sites in addition to the sites already open in the TRIO-US network. This study is a dose frequency optimization trial of nivolumab in patients with Stage IIIB or Stage IV squa…

01/27
2017

Stand Up To Cancer Ushers In New Approach to Research with Calls by AACR for SU2C Dream Teams on “Interception” of Pancreas and Lung Cancers, Each Funded at $7 Million

Stand Up To Cancer (SU2C) broke new ground today when the American Association for Cancer Research (AACR), its scientific partner, announced to the cancer research community funding to support new Dream Teams focused on “cancer interception…

01/27
2017

Advanced NSCLC Patients Live Longer When Treated, but Proportion of Untreated Patients Rising

Patients with advanced non-small cell lung cancer (NSCLC) who receive treatment live longer than those who remain untreated, but the proportion of NSCLC patients with advanced disease who don’t receive treatment has been rising in the Unit…

01/24
2017

Multimillion Dollar Grant Awarded from the National Cancer Institute for Translational Research at UCLA and in TRIO-US

The December, 2016 issue of  THORACIC ONCOLOGY TRANSLATIONAL RESEARCH AT UCLA & TRIO-US announces that the National Cancer Institute has awarded funding to study determinants of benefit from PD-1 inhibitors in patients at UCLA (includ…

01/10
2017

Personalized Medicine Impacting Study Conduct

“We are moving to an era where we use molecular analysis of patient samples either to enroll people in trials or understand how drugs work or don’t work,” said Ross Levine, M.D., a physician-scientist at the Memorial Slo…

12/20
2016

Immunotherapy Agent Improved Quality of Life in Lung Cancer Study

  There was a quality of life improvement for patients with non-small cell lung cancer who were treated with Keytruda compared to those who had standard chemotherapy, according to new data from the trial presented at the IASLC 17th Wo…

12/20
2016

Boehringer Ingelheim HCP Survey: Nearly 20% Of Newly Diagnosed Lung Cancer Patients Tested For EGFR Mutations At Risk Of Missing Out On Personalised Treatments For Their Disease

Recent international survey showed high global EGFR testing rates prior to first-line lung cancer therapy but highlighted a shortfall in the number of test results received before deciding on therapy. Nearly one in five patients are at r…

12/15
2016

Living Under a Cloud: Examining Air Pollution’s Effects on Lung Cancer

"One takeaway that I find interesting is that there’s been an emphasis on advance screening to detect early-stage lung cancer, so I think that we’re going to be seeing more of it. These are the people who we found air pollution ha…

12/9
2016

ARIAD’s Investigational Medicine Brigatinib Demonstrated 15.6 Month Systemic Median Progression-Free Survival in ALTA Study

New from the World Conference on Lung Cancer: Positive clinical trial results for ALK+ NSCLC patients who had been treated with and experienced disease progression on their most recent crizotinib therapy. Read the article: http://www.bus…

12/9
2016

AstraZeneca pill slashes lung cancer progression in study

AstraZeneca's pill Tagrisso cut the risk of lung cancer progressing by 70 percent compared to standard chemotherapy in a major clinical trial. The medicine is designed to help cancer patients with EGFR mutations that are very common in C…

12/9
2016

New application of existing drug offers personalized therapy for lung cancer

A subset of lung tumors is exquisitely sensitive to a class of recently approved anti-cancer drugs. Researchers at the CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences in Vienna and the Ludwig Institute for Ca…

12/9
2016

ABOUND Data Presented at the World Conference on Lung Cancer Further Explores Safety and Efficacy of ABRAXANE® for Challenging Patient Populations

  "These early data from the ABOUND clinical trial program are very encouraging, as they are consistent with the findings related to these hard to treat non-small cell lung cancer patient subgroups seen in the pivotal ABRAXANE Phase…

12/8
2016

Updated KEYTRUDA® (pembrolizumab) Data in Small Cell Lung Cancer and Mesothelioma Presented at 17th World Conference on Lung Cancer

“As data from our initial trials exploring KEYTRUDA mature, we are encouraged to see durable clinical activity in difficult-to-treat cancers such as small cell lung cancer and malignant pleural mesothelioma, where new treatments are clear…

11/11
2016

Microsoft Shows Searches Can Boost Early Detection of Lung Cancer

Patients may reveal early symptoms by looking on web for medical terms and treatment. Lung cancer can be detected a year prior to current methods of diagnosis in more than one-third of cases by analyzing a patient's internet searches for…

09/19
2016

Liquid Biopsy — “Powerful Tool” In Precision Lung Cancer Therapy, Study Shows

A new study suggests that liquid biopsies may yield more actionable data than results from genetic sequencing tests of tissue biopsies in patients with non-small cell lung cancer (NSCLC), especially as the disease progresses. Read more: …

09/19
2016

IASLC Lung Cancer Newsletter: September, 2016

Highlights include: Interview with Dr. Alice Shaw regarding new ALK-inhibitor recently approved as a second line treatment. The FDA’s new tobacco rule which extends its regulatory authority to all tobacco products, including small an…

09/13
2016

Blue Ribbon Panel Presentation to National Cancer Advisory Board for Cancer Moonshot

The Blue Ribbon Panel presented its report to the National Cancer Advisory Board on September 7, 2016. The report describes 10 transformative research recommendations for achieving the Cancer Moonshot’s ambitious goal of making a decade's…

09/13
2016

ARIAD Completes Rolling Submission of New Drug Application for Brigatinib to the U.S. Food and Drug Administration

A new treatment option for ALK-positive NSCLC patients from ARIAD is in the hands of the FDA: Read more: http://finance.yahoo.com/news/ariad-completes-rolling-submission-drug-113500651.html…



Read More